Advaxis, Inc. (NASDAQ:ADXS) shares saw unusually-strong trading volume on Friday . Approximately 16,877,475 shares changed hands during trading, an increase of 555% from the previous session’s volume of 2,575,265 shares.The stock last traded at $0.77 and had previously closed at $0.63.
Separately, Zacks Investment Research downgraded shares of Advaxis from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th.
The firm’s 50 day simple moving average is $0.38 and its two-hundred day simple moving average is $1.01. The stock has a market capitalization of $11.61 million, a P/E ratio of -0.04 and a beta of 3.43.
A number of institutional investors have recently modified their holdings of ADXS. JPMorgan Chase & Co. raised its stake in Advaxis by 53,633.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after buying an additional 50,952 shares during the period. Sabby Management LLC boosted its holdings in Advaxis by 3,547.9% in the third quarter. Sabby Management LLC now owns 1,521,982 shares of the biotechnology company’s stock worth $403,000 after acquiring an additional 1,480,260 shares in the last quarter. Vanguard Group Inc. grew its stake in Advaxis by 71.1% in the second quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock valued at $481,000 after acquiring an additional 95,607 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Advaxis by 143.7% in the second quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock valued at $1,047,000 after acquiring an additional 295,444 shares during the period. 30.33% of the stock is owned by institutional investors and hedge funds.
Advaxis Company Profile (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Featured Article: How big is the FinTech market?
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.